天津医药 ›› 2015, Vol. 43 ›› Issue (3): 333-336.doi: 10.11958/j.issn.0253-9896.2015.03.030

• 综述 • 上一篇    

血管内皮生长因子抑制剂治疗银屑病的研究进展#br#

李珺莹, 李红#br# #br#   

  1. 天津市中医药研究院附属医院皮肤科 (邮编 300120
  • 收稿日期:2014-09-02 修回日期:2014-11-03 出版日期:2015-03-15 发布日期:2015-03-15
  • 通讯作者: 李珺莹 E-mail:doctorlijy@sina.com
  • 作者简介:李珺莹 (1978), 女, 主治医师, 硕士, 主要从事银屑病及免疫性皮肤病的研究
  • 基金资助:
    天津市中医药管理局科技基金 (13020

Advances of vascular endothelial growth factor inhibitors in the treatment of psoriasis

LI JunyingLI Hong   

  1. Department of Dermatology, The Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin 300121, China
  • Received:2014-09-02 Revised:2014-11-03 Published:2015-03-15 Online:2015-03-15
  • Contact: LI Junying E-mail:doctorlijy@sina.com

摘要: 银屑病是一种常见的炎症性免疫相关性皮肤病, 血管生成是银屑病致病的一个关键因素。血管内皮生长因子(VEGF)在银屑病患者的皮损和血浆中显著升高, 许多病例报告表明 VEGF 抑制剂治疗银屑病有效。现有的 VEGF 抑制剂主要有 3 大类, 包括抗 VEGF 单克隆抗体、 VEGF 受体拮抗剂和酪氨酸激酶抑制剂。本文综述了目前 VEGF 抑制剂治疗银屑病的临床应用现状及前景展望。

关键词: 银屑病, 血管内皮生长因子类, 血管内皮生长因子抑制剂

Abstract: Psoriasis is a common inflammatory autoimmune disease. Angiogenesis is known to be a key pathogenic fea⁃ ture of psoriasis. The elevation of vascular endothelial growth factor (VEGF) has been demonstrated in the skin and plasma of patients with psoriasis. A number of case reports have indicated that VEGF inhibitor is effective in patients with psoriasis. VEGF inhibitors are consisted of three categories: anti-VEGF monoclonal antibodies, VEGF receptor antagonists and tyro⁃ sine kinase inhibitors. This article reviewed the current clinical application and therapeutic potential of VEGF inhibitors in psoriasis .

Key words: psoriasis, vascular endothelial growth factors, VEGF inhibitor